List of Excipients in Branded Drug EXCEDRIN MIGRAINE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Select Corporation	EXCEDRIN MIGRAINE	acetaminophen, aspirin, and caffeine	52904-871	BENZOIC ACID
Select Corporation	EXCEDRIN MIGRAINE	acetaminophen, aspirin, and caffeine	52904-871	CARNAUBA WAX
Select Corporation	EXCEDRIN MIGRAINE	acetaminophen, aspirin, and caffeine	52904-871	CELLULOSE, MICROCRYSTALLINE
Select Corporation	EXCEDRIN MIGRAINE	acetaminophen, aspirin, and caffeine	52904-871	DIMETHICONE
Select Corporation	EXCEDRIN MIGRAINE	acetaminophen, aspirin, and caffeine	52904-871	FD&C BLUE NO. 1
Select Corporation	EXCEDRIN MIGRAINE	acetaminophen, aspirin, and caffeine	52904-871	HYDROXYPROPYL CELLULOSE
Select Corporation	EXCEDRIN MIGRAINE	acetaminophen, aspirin, and caffeine	52904-871	HYPROMELLOSE

Excedrin Migraine Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Excedrin Migraine is a U.S. over-the-counter combination product containing acetaminophen, aspirin, and caffeine. Its commercial value is driven by brand recognition, OTC regulatory status, and dosage-form execution rather than a durable excipient patent estate. The principal opportunity for suppliers and competing manufacturers is to improve tablet manufacturability, disintegration, coating, sensory performance, and supply resilience without changing the established active-ingredient profile.

What is the active and inactive ingredient profile of Excedrin Migraine?

Excedrin Migraine contains 250 mg of acetaminophen, 250 mg of aspirin, and 65 mg of caffeine per caplet. The product is marketed for temporary relief of migraine headache and associated symptoms under a U.S. FDA-approved OTC labeling framework.[1]

Component	Function or commercial relevance
Acetaminophen, 250 mg	Analgesic and antipyretic
Aspirin, 250 mg	Analgesic and anti-inflammatory agent
Caffeine, 65 mg	Analgesic adjuvant
Microcrystalline cellulose	Tablet filler and compression aid
Crospovidone	Superdisintegrant
Sodium starch glycolate	Superdisintegrant
Povidone	Binder
Colloidal silicon dioxide	Glidant and moisture-control aid
Stearic acid	Lubricant
Sodium lauryl sulfate	Wetting and processing aid
Polysorbate 80	Surfactant
Hypromellose	Film-coating polymer
Titanium dioxide and colorants	Opacity and product identification
Carnauba wax and related coating materials	Surface finish and gloss

The exact inactive-ingredient list can vary by manufacturing site, label revision, market, or presentation. Product development should use the current FDA label and DailyMed record as the controlling commercial references.[1,2]

Which excipients are most important to product performance?

The highest-value excipient functions are disintegration, compression, coating integrity, and lubricant control.

Excedrin Migraine combines three active ingredients with different physical and chemical properties. Acetaminophen can present compression and dissolution challenges. Aspirin is sensitive to moisture and can hydrolyze to salicylic acid and acetic acid under adverse storage conditions. Caffeine has different particle characteristics and can segregate in a poorly designed powder blend.

A robust formulation therefore requires:

1. A high-performing disintegrant system.
2. Controlled lubricant concentration and blending time.
3. Moisture-managed processing and packaging.
4. A coating system that protects the caplet without slowing release.
5. Particle-size and density controls that limit segregation.

Crospovidone and sodium starch glycolate provide a dual-disintegrant strategy. A competing manufacturer could evaluate crosslinked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, croscarmellose sodium, or optimized combinations. The commercial objective would be faster and more consistent breakup while preserving the dissolution profile expected for an immediate-release analgesic.

What excipient strategies can improve Excedrin Migraine manufacturing?

Can a competing product use different excipients?

Yes. Excipients in an OTC combination product generally can be changed if the finished product remains compliant with the applicable FDA requirements, approved labeling, quality specifications, and relevant bioequivalence or drug-product standards. The formulation must not create a meaningful change in safety, efficacy, identity, strength, quality, or performance.

The most practical alternatives are:

Formulation target	Candidate strategy	Commercial benefit
Faster disintegration	Croscarmellose sodium, crospovidone, low-substituted HPC	Potentially shorter disintegration time
Better flow	Spray-dried mannitol, silicified MCC, colloidal silica	Higher tablet throughput and lower weight variation
Reduced sticking	Optimized magnesium stearate or sodium stearyl fumarate	Lower punch adhesion and tooling maintenance
Improved wetting	Polysorbate 80, sodium lauryl sulfate, poloxamers	More consistent dissolution
Lower moisture exposure	High-barrier film coating and blister packaging	Better aspirin stability
Improved swallowability	Low-friction hypromellose coating, smaller caplet geometry	Better consumer acceptability
Clean-label positioning	Fewer colorants, alternative coating systems, synthetic-dye reduction	Retail and consumer differentiation
Supply resilience	Dual-source excipient qualification	Lower manufacturing interruption risk

The leading technical constraint is preservation of the immediate-release profile. A formulation that uses excessive binder, hydrophobic lubricant, or dense coating may delay release of one or more active ingredients.

Which excipient changes have the strongest commercial potential?

Three areas have the clearest return potential.

First, moisture control is important because aspirin degradation can reduce potency and create degradation products. High-barrier unit-dose blister packaging, desiccant-supported bottles, and low-moisture coating systems can reduce stability risk. Packaging is not an excipient strategy in the narrow sense, but it is a critical part of the same product-protection program.

Second, rapid-dissolution positioning can support premium presentations. A caplet that disintegrates rapidly, has consistent dissolution, and is easier to swallow could support a differentiated OTC product, although marketing claims would require substantiation and regulatory review.

Third, supply-chain substitution can reduce cost. Microcrystalline cellulose, crospovidone, sodium starch glycolate, hypromellose, colloidal silicon dioxide, and coating pigments are widely supplied materials. Qualifying multiple vendors can reduce exposure to shortages, regional capacity constraints, and raw-material price changes.

What FDA regulatory pathway applies to Excedrin Migraine?

Excedrin Migraine is an OTC drug product with an FDA-approved application and product-specific labeling. The active ingredients are established analgesic and stimulant ingredients, but the three-ingredient combination and migraine indication require compliance with the product’s approved regulatory framework.[1,3]

Is Excedrin Migraine an OTC monograph product?

The active ingredients individually have long histories under OTC drug monographs. However, Excedrin Migraine is associated with an FDA-approved product application and product-specific labeling rather than being treated solely as an unapproved private-label monograph product. A competing manufacturer must assess whether its product can rely on an applicable OTC monograph, requires an abbreviated or full application, or must proceed under another FDA pathway.

A formulation change that preserves the same active ingredients and dosage form may still require regulatory work if it changes inactive ingredients, dissolution, labeling, manufacturing controls, or product performance. The regulatory burden depends on the product’s legal basis and the magnitude of the change.

Does the FDA require excipient approval?

The FDA does not approve excipients as independent therapeutic products. It reviews excipients as components of drug products. Acceptability depends on prior use, concentration, route, dosage form, safety record, and the proposed product.

The strongest regulatory position generally comes from excipients with established use in immediate-release oral tablets at comparable concentrations. Novel excipients or materially higher exposures create greater documentation requirements.

What patents protect Excedrin Migraine?

The original commercial protection for Excedrin Migraine is unlikely to provide a current barrier comparable to a modern patented small-molecule product. Acetaminophen, aspirin, and caffeine are old active ingredients, and the basic three-component analgesic combination has been commercially known for decades.

Are there active Orange Book patents for Excedrin Migraine?

The Orange Book must be checked against the current FDA application record before relying on a patent conclusion. Product-specific patent listings, if any, would be tied to the approved application rather than to the active ingredients themselves.[4]

The commercial risk profile is distinct from a conventional branded prescription drug:

IP category	Likely relevance to Excedrin Migraine
Active-ingredient composition patents	Minimal; ingredients are long-established
Basic combination patents	Historical relevance; likely expired
Core tablet formulation patents	Possible historical relevance; must be verified by jurisdiction
Method-of-use patents	Limited because the indication is an established OTC migraine indication
Manufacturing-process patents	Potentially relevant but difficult to identify from labeling
Trademark and trade dress	High practical relevance
Excipient know-how	Potentially valuable as confidential manufacturing information
Packaging and quality systems	Commercially relevant, usually not product-blocking patents

Patent expiry should be evaluated family by family. A historical patent covering a combination, coating, or manufacturing process does not create a current barrier unless an unexpired claim covers the proposed product or process in the target jurisdiction.

When does Excedrin Migraine lose exclusivity?

Excedrin Migraine’s principal exclusivity is commercial rather than patent-based. The brand is protected by the Excedrin trademark, consumer recognition, retail placement, advertising, and manufacturing scale.

The product’s practical loss-of-exclusivity timeline is:

Event	Strategic effect
Historical FDA approval and OTC launch	Established the product-specific migraine positioning
Expiry of historical formulation or combination patents	Opened the field to competing formulations
Availability of OTC alternatives	Shifted competition to price, distribution, and brand
Current market	Brand differentiation depends on trust, convenience, and retail execution
Future formulation launches	Could create premium niches without restoring molecule-level exclusivity

A competitor does not need to duplicate every inactive ingredient. It must produce a compliant product with the same active ingredients, appropriate quality, acceptable performance, and legally supportable labeling.

What generic entry risks exist for Excedrin Migraine?

Generic and store-brand entry risk is high because:

• The active ingredients are inexpensive and widely available.
• The dosage form is a conventional oral caplet.
• The active strengths are fixed and commercially familiar.
• The product does not depend on a complex delivery device.
• The principal excipients are common pharmaceutical materials.
• Consumers can substitute based on price and retailer recommendation.

The main barriers are operational rather than scientific. These include aspirin stability, active-ingredient uniformity, dissolution matching, tablet capping or sticking, coating defects, and flavor or swallowability complaints.

What could delay a generic launch?

A launch can be delayed by:

1. Failure to match dissolution across all three active ingredients.
2. Aspirin degradation during accelerated or long-term stability studies.
3. Inadequate control of caffeine segregation.
4. Inconsistent tablet hardness and disintegration.
5. Labeling errors involving acetaminophen overdose and aspirin bleeding warnings.
6. Manufacturing changes that trigger additional FDA review.
7. Trademark, trade-dress, or packaging disputes.
8. Retailer qualification requirements.

Paragraph IV litigation is less central than for a prescription product with listed patents. If an applicant relies on an ANDA or another abbreviated pathway and certifies against an unexpired listed patent, a Paragraph IV dispute could arise. The commercial probability depends on whether the current reference product has enforceable listed patents, not merely whether historical patents existed.

Which companies are positioned to challenge Excedrin Migraine?

Competition can come from three groups:

Competitor group	Examples	Competitive method
Branded analgesic companies	Bayer, Johnson & Johnson consumer brands, Haleon	Brand advertising and indication breadth
Retailer private labels	CVS, Walgreens, Walmart, Amazon and regional chains	Lower price and shelf placement
Generic manufacturers	Perrigo, Dr. Reddy’s, L. Perrigo affiliates and other OTC suppliers	Contract manufacturing and private-label supply
Alternative dosage-form developers	Softgel, effervescent, powder, or orally disintegrating tablet manufacturers	Convenience and sensory differentiation

The most credible challenger is usually a private-label or contract-manufactured caplet rather than a technically complex reformulation. A softgel or effervescent product could command a premium, but it introduces greater stability, packaging, and manufacturing complexity.

What licensing and commercial opportunities exist?

Publicly disclosed licensing economics specific to Excedrin Migraine are limited. Haleon owns the Excedrin brand portfolio following the separation of GSK’s consumer-healthcare business.[5] The more realistic commercial opportunities are supply and development agreements rather than licenses to the core active ingredients.

Potential deal structures include:

• Preferred-supplier agreements for microcrystalline cellulose, superdisintegrants, or coating polymers.
• Dual-source qualification contracts for critical excipients.
• Contract manufacturing of private-label acetaminophen-aspirin-caffeine products.
• Technology licenses for rapid-disintegration or moisture-protection systems.
• Packaging agreements using high-barrier blister systems.
• Regional distribution or retailer-exclusive products.
• Co-development of dye-reduced, sugar-free, or swallowability-focused presentations.

The strongest supplier value proposition is measurable manufacturing performance: lower rejection rates, faster tablet press speeds, improved dissolution consistency, or longer stability. A generic excipient without validated process advantages is more exposed to price competition.

How strong is the patent estate for Excedrin Migraine?

The estate is weak as a molecule and combination platform but stronger as a brand and manufacturing system.

Asset	Relative strength
Acetaminophen, aspirin, and caffeine composition	Very weak patent position
Conventional immediate-release caplet	Weak unless a narrow process claim applies
Specific excipient combination	Potentially protectable but likely narrow
Moisture-protection process	Moderate if claims are valid and unexpired
Rapid-disintegration formulation	Moderate if supported by unexpected performance
Packaging and trade dress	Moderate to strong commercial protection
Excedrin trademark	Stronger than formulation exclusivity
Manufacturing know-how	Potentially strong if kept confidential

A new formulation patent would need claims that distinguish over ordinary combinations of known tablet excipients. Broad claims to “a tablet comprising acetaminophen, aspirin, caffeine, and a disintegrant” would face substantial prior-art risk. More defensible claims could focus on defined particle-size distributions, disintegration thresholds, dissolution parameters, moisture limits, coating architecture, or stability outcomes.

What is the commercial outlook for excipient suppliers?

The addressable opportunity is recurring volume rather than high-margin exclusivity. Excipients used in a mass-market OTC analgesic can generate meaningful sales when the supplier achieves approved status across multiple manufacturing sites or private-label customers.

The most attractive targets are:

1. Superdisintegrants with reliable performance at low use levels.
2. Direct-compression fillers that reduce processing steps.
3. Low-moisture coating systems.
4. Lubricants that reduce sticking without slowing dissolution.
5. High-barrier packaging components.
6. Excipient systems that support alternate sourcing without reformulation.
7. Coating technologies that reduce synthetic colorants while preserving product identity.

Revenue exposure for Haleon’s Excedrin Migraine product is not separately disclosed in Haleon’s public reporting. It should therefore be modeled through brand-level, category-level, retailer, shipment, and market-share data rather than treated as a separately reported financial segment.[5]

Key Takeaways

• Excedrin Migraine contains 250 mg acetaminophen, 250 mg aspirin, and 65 mg caffeine per caplet.
• Its commercial protection depends more on trademark, distribution, consumer trust, and manufacturing scale than on active-ingredient patents.
• The core excipient opportunity is to improve disintegration, dissolution, tablet compression, coating, moisture control, and supply resilience.
• Aspirin stability and immediate-release performance are the main technical constraints.
• Generic and private-label entry risk is high because the active ingredients and dosage form are well established.
• Formulation patents would likely need narrow, performance-based claims to withstand prior-art challenges.
• The most practical licensing opportunities involve excipient supply, contract manufacturing, packaging, and differentiated dosage forms.
• Haleon does not separately disclose Excedrin Migraine revenue in its public financial reporting.

FAQs

Can Excedrin Migraine be reformulated without changing its active ingredients?

Yes. A manufacturer can evaluate different excipients, coating systems, tablet dimensions, and packaging configurations, but the finished product must meet FDA quality, labeling, stability, and performance requirements.

Is aspirin the main excipient-related stability risk?

Aspirin is the principal chemical stability concern because moisture can accelerate hydrolysis. Excipient moisture content, processing humidity, coating permeability, bottle closure, and blister-barrier performance all affect risk.

Can an excipient supplier patent a new Excedrin Migraine formulation?

Potentially. Patentability would depend on novelty, non-obviousness, written description, enablement, and claim scope. Claims based only on routine substitution of one common tablet excipient for another would face significant validity risk.

Are softgels a commercially attractive alternative to the Excedrin Migraine caplet?

They may offer swallowability and consumer differentiation, but softgels create added development issues involving aspirin compatibility, suspension uniformity, shell stability, fill viscosity, packaging, and long-term degradation control.

Can a retailer sell a private-label equivalent of Excedrin Migraine?

A retailer can market a private-label equivalent if the product complies with the applicable FDA pathway, labeling requirements, quality standards, trademark rules, and manufacturing obligations. It cannot copy Excedrin trade dress or imply unauthorized brand affiliation.

References

1. Haleon Consumer Healthcare. (2024). Excedrin Migraine acetaminophen, aspirin, and caffeine tablet, film coated: Drug facts and inactive ingredients. DailyMed, U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-343

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. Center for Drug Evaluation and Research.

5. Haleon plc. (2024). Annual report and accounts 2023. https://www.haleon.com/investors/reports-and-presentations/annual-report/